Search - tctmd.com

Displaying 1 - 20 of 44

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Discharge Safe as Early as a Day After Primary PCI for STEMI

News Daily News

Discharge Safe as Early as a Day After Primary PCI for STEMI

December 15, 2021

December 2021 News Roundup

News Opinion CV Team Dispatch

December 2021 News Roundup

December 01, 2021

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

News Conference News AHA 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

November 18, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

COVID-19: TCTMD’s Dispatch for October Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 3

October 18, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

September 2021 News Roundup

News Opinion CV Team Dispatch

September 2021 News Roundup

September 01, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 4

August 22, 2021

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

News Daily News

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Michael O'Riordan

August 03, 2021

July/August 2021 News Roundup

News Opinion CV Team Dispatch

July/August 2021 News Roundup

August 01, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 1

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 1

August 01, 2021

Big Downturn in CVD Procedures Seen During COVID-19’s First Wave

News Daily News

Big Downturn in CVD Procedures Seen During COVID-19’s First Wave

Michael O'Riordan

July 01, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.